Mati Therapeutics Expands Intellectual Property Portfolio with 114 Patents Issued
AUSTIN, Texas--(BUSINESS WIRE)--Mati Therapeutics Inc. (“Mati”) announced that its international patent portfolio has grown to 114 issued patents, including recently granted U.S. Patent No. 9,849,082, titled “Nasolacrimal Drainage System Implants for Drug Therapy." This patent, which will not expire until 2027, relates to a drug delivery system for administering an ophthalmic drug through a hydrogel lacrimal implant into one or both puncta (tear ducts) of the eye. With the issuance of this pate